PreprintPDF Available
Preprints and early-stage research may not have been peer reviewed yet.

Abstract and Figures

This paper argues that “ASEA redox Supplement” (ARS) may show comparable or even stronger beneficial effects (with less or none adverse effects) than corticosteroids in children with Duchenne Muscular Dystrophy (DMD) and Becker muscular dystrophy (BMD). This paper presents a third case report on the effects of an ionized “saline water” called “ASEA redox Supplement®” (ARS) oral solution in a ~3-year-old boy with DMD from town Slobozia [URL2], Romania. In vitro studies showed that ARS is a very potent selective NRF2 activator, thus a very potent (indirect) antioxidant and cytoprotective: the studies conducted in vivo also support this main pharmacological mechanism of ARS, with no toxicity up to high doses, in contrast with the much more toxic corticosteroids. From the first months of ARS treatment, the main rhabdomyolysis markers (with very high initial serum levels) dropped significantly, with no found toxicity until the present. Before starting adjuvant therapy with oral ARS, this boy-patient was already prescribed by his attending neurologist a combined therapy with: L-carnitine (1g/day) & Vitamin D3 (1000IU/day) & calcium-magnesium oral supplement (5ml/day) & plant-extracts hepatoprotective syrup (5ml/day) & coenzyme Q10 (30mg/day) from the last week of February 2019 (thus from approximately 5 months earlier than the moment in which ARS therapy was initiated). This previous combined therapy of dietary supplements (DSs) also showed a promising decrease in rhabdomyolysis serum markers (RSMs) (which is also an important fact with implications for other children with DMD who may potentially benefit from this combined set of DSs): however, when the calcium-magnesium oral supplement was replaced by a combination of ARS (30ml/day ~ 2.5ml/kg/day) & omega-3 fatty acids (185mg/day with a DHA: EPA ratio of approx. 5-to-1) from August 1st, 2019, the RSMs decrease was quite spectacular (when compared to the anterior decrease) when measured in December 2nd, 2019 at “Victor Gomoiu” Pediatric Hospital (from Bucharest, Romania). This paper continues the work of other past articles/preprints of the same author. This paper belongs to a series of three cases on Asea effects in DMD children-patients: https://www.researchgate.net/publication/325371161 (1st case - preprint), https://www.researchgate.net/publication/334596031 (1st case - CJBRT article), https://www.researchgate.net/publication/334773748 (1st case - periodic updates), https://www.researchgate.net/publication/335502350 (2nd case - preprint), https://www.researchgate.net/publication/340902127 (3rd case - preprint); See also: https://www.researchgate.net/publication/336990483 and https://www.researchgate.net/publication/337026408 (ppt on Asea), https://www.researchgate.net/publication/339592997 (on possible testing of NRF2 activators in COVID-19)
Content may be subject to copyright.
1
A Third Case Report Regarding the Effects
of “ASEA redox Supplement” in a ~3-year
old boy with Duchenne Muscular Dystrophy
from town Slobozia, Romania (preprint)
*
DOI: 10.13140/RG.2.2.26419.99367 [URL-RG]
*
This article preprint version: 1.0 (24.04.2020)
(latest article version is always available at this URL;
version 1.0 released on 24.04.2019)
*
Authors: Andrei-Lucian Drăgoi
1
,*
Affiliations: * MD pediatrician specialist affiliated to The
Emergency County Hospital Târgoviște (SJUT); working from
9.03.2020 until present in the Department of Pediatric Infectious
Diseases of SJUT;
*Correspondence to: dr.dragoi@yahoo.com
*
1st motto: „ASEA works at some fundamental level in the body
that we may never understand” (2011, Dr. Chase N. Peterson MD
[1999-2014], the former president of the University of Utah from
1983 to 1991)
2nd motto: „ASEA is based on technology that the scientist don’t
yet understand.” (2013, Dr. A.S. Narain Naidu MD Phd,
microbiologist, immunologist and researcher, author of the
reference volume „Redox Life”)
3rd motto: „We didn’t think that drinking ASEA would shift
metabolites chronically. We thought it would do something during
exercise, but not after a week of drinking it [without concomitant
exercise: author’s note]. After working with the bioinformatics
statistical division, we were able to determine that drinking ASEA
over one week caused a shift in 43 metabolites, not a little shift: it
was a large shift that caught us by surprise.” (David Christopher
Nieman [URL2, URL3] PhD and full professor at the College of Health
Sciences at Appalachian State University, and director of the
Human Performance Lab at the North Carolina Research Campus
(NCRC) in Kannapolis, NC) (video interview URL, from minute
5:40)
4th motto: „Pediatrics what a joy, what a feeling of
accomplishment when helping Nature heal its children or prevent
their diseases and accidents!” (Andrei-Lucian Drăgoi, pediatrician
specialist and independent researcher)
[
1
] Email: dr.dragoi@yahoo.com; Main pages: [Science]
dragoii.com; rg.dragoii.com; academia.dragoii.com;
vixra.dragoii.com; gsj.dragoii.com; [Music] smp.dragoii.com,
se.dragoii.com; [CVs] cvrg.dragoii.com; ej.dragoii.com,
bj.dragoii.com;
Abstract
This paper argues that “ASEA redox Supplement” (ARS) may
show comparable or even stronger beneficial effects (with less or
none adverse effects) than corticosteroids in children with
Duchenne Muscular Dystrophy (DMD) and Becker muscular
dystrophy (BMD). This paper presents a third case report on the
effects of an ionized “saline water” called “ASEA redox
Supplement®” (ARS) oral solution in a ~3-year-old boy with DMD
from town Slobozia [URL2], Romania. In vitro studies showed that
ARS is a very potent selective NRF2 activator, thus a very potent
(indirect) antioxidant and cytoprotective: the studies conducted in
vivo also support this main pharmacological mechanism of ARS,
with no toxicity up to high doses, in contrast with the much more
toxic corticosteroids.
From the first months of ARS treatment, the main
rhabdomyolysis markers (with very high initial serum levels)
dropped significantly, with no found toxicity until the present.
Before starting adjuvant therapy with oral ARS, this boy-patient
was already prescribed by his attending neurologist a combined
therapy with: L-carnitine (1g/day) & Vitamin D3 (1000IU/day) &
calcium-magnesium oral supplement (5ml/day) & plant-extracts
hepatoprotective syrup (5ml/day) & coenzyme Q10 (30mg/day)
from the last week of February 2019 (thus from approximately 5
months earlier than the moment in which ARS therapy was
initiated). This previous combined therapy of dietary supplements
(DSs) also showed a promising decrease in rhabdomyolysis serum
markers (RSMs) (which is also an important fact with implications
for other children with DMD who may potentially benefit from this
combined set of DSs): however, when the calcium-magnesium oral
supplement was replaced by a combination of ARS (30 ml/day ~
2.5 ml/kg/day) & omega-3 fatty acids (185 mg/day with a
DHA:EPA ratio of approx. 5-to-1) from August 1st, 2019, the
RSMs decrease was quite spectacular (when compared to the
anterior decrease) when measured in December 2nd, 2019 at “Victor
Gomoiu” Pediatric Hospital (from Bucharest, Romania).
This paper continues the work of other past articles/preprints of
the same author [
1
,
2
,
3
,
4
,
5
,
6
].
The main conclusions of this third case report (on ARS
effect in boys with DMD) are essentially the same as those
emitted in the preprint dedicated to the 2nd case report on ARS
in another 5-year old boy with DMD:
(1a) ARS has remarkable antioxidant and immunomodulatory
effects and should be studied on larger groups of children with
DMD under the age of 4 years old (but also on other age groups of
children and even young adults), as an alternative to early
corticosteroids;
(1b) ARS should be studied as single adjuvant therapy, BUT
ALSO in various combinations with other DSs (with cytoprotective
and antioxidant properties) like: L-carnitine, vitamine D3, omega-3
fatty acids, coenzyme Q10 etc (given the potential beneficial
synergy between these all these DSs [including ARS] on DMD);
(2) Given its immunomodulatory effect (NRF2 selective
activation and NF-kB inhibition), ARS deserves future cohort
studies on its potential to at least partially replace corticosteroids
and other non-steroidal immunosuppressants in many types of
pulmonary/renal/hepatic/ articular/skin autoimmune and even
malignant diseases of both children and adults;
(3) Given its very strong antioxidant effects (by highly selective
NRF2 potent activation), ARS deserves future cohort studies on
acute/chronic diseases that imply high levels of tissular oxidative
2
stress, especially some acute/chronic cardiovascular and respiratory
diseases like acute myocardial infarction with acute/chronic heart
failure, stroke, Chronic Obstructive Pulmonary Disease (COPD),
asthma etc. of both children and adults (so that ARS may help
millions and even billions worldwide).
*
For an introduction to DMD, NF-kB, NRF2, ARS and the 1st
case report on ARS effects in DMD see the main references of this
paper [1, 2]. All the essential aspects of this 3rd case report on
ARS effects in DMD are included in the next table (see next
page).
(Table 1. The essential aspects of this 3rd case report on ARS effects in DMD)
Table 1. The essential aspects of this 3rd case report on ARS effects in DMD
PEDIATRIC
CONSULTS
by Dr. Andrei-
Lucian Drăgoi
Anamnestic and clinical essential aspects
of this case
Paraclinical essential aspects of
this case
Management --
essential measures
recommended by dr.
Dragoi
Consult no. 1 by
dr. Dragoi on
31.07.2019
(home consult)
Age: 3 years old (birth date: 2.07.2016)
Sex: male
Birth location: Slobozia, Romania
*
Diagnosis: Duchenne muscular dystrophy
(DMD) (genetic testing in March 2019
with DMD genotype confirmation in April
2019 [when he was 2 years and 9 months
old]) *
Anamnesis:
- according to his mother, this DMD boy
had a maternal uncle who “walked on his
toes until the age of 6-7 years old and lost
his capacity to walk at the age of ~7 years
old and died at the age of 20 years old
- ALTHOUGH the CK (2600U/l) and
ASAT (780U/l) serum levels (SLs) of this
boy were significantly increased from
the first day after birth (according to the
maternity medical file of the child), these
marked RSMs and the suggestive history
element (the deceased maternal uncle)
were ignored by both the neonatologist
and his family doctor until 22.01.2019
(Age: 2 years &months) when a
dermatologist discovered (by routine
screening) very high ASAT SL (970U/l)
and ALAT SL (844.5 U/l); the boy was
then sent on 30.01.2019 to the “Victor
Babes” Infectious Diseases Hospital
from Bucharest (Romania) for extensive
screening on infectious liver diseases
(with negative serology for hepatitis
B&C and also negative for Toxocara);
after ruling out these liver diseases, the
infectionist send this boy on 27.02.2019
to “Victor Gomoiu” pediatric hospital
for muscular dystrophy screening;
-first neurologic consult in 27.02.2019 at
“Victor Gomoiu” pediatric hospital
-last neurologic consult (until Dr. Dragoi’s
consult) in 22.05.2019 at the same “Victor
Gomoiu” pediatric hospital
-up-to-date vaccine status
*
Clinical aspects (the essentials):
Genetic test result (blood sample
collected on 1.03.2019; Age:~2
years& 8 months; result ready on
19.04.2019 at ~2 years& 9 months):
heterozygous complete deletion of
49th and 50th exons of dystrophin
gene (dys-gene) (which is generally
the most frequent type of exon-
deletion from all known DMD cases
worldwide): furthermore, exon-
deletions are also the most frequent
type of dys-gene mutation in DMD
patients with more than 50% of all
known DMD patients worldwide
having various types of exon-
deletions [URl1, URl2, URl3,
URL4]); the boy’s mother was also
demonstrated to carry exactly the
same 49th&50th exons deletion and
also demonstrated with a slight
elevation of both ASAT and ALAT
serum levels (possibly caused by this
same carried dys-gene mutation) and
high total IgE serum levels;
Important note: although not
specified in the genetic test result,
this 49th&50th exons deletion is
probably an in-frame deletion:
however, the clinical evolution (with
loss of ambulation at 7 years old of
age and death at 20 years old of age)
of his maternal uncle clearly
indicates that this boy has a severe
DMD phenotype (as the very high
serum levels of his rhabdomyolysis
markers [RMs] also indicate); given
all these previous arguments, the
dystrophin of this boy is probably
significantly shorter than the normal
dystrophin [URL1, URL2, URL3];
*
Heart ultrasound (1) (Age: 1
week): “normal”.
Heart ultrasound (2) (28.09.2016;
Age: 7 months) (selection):
ventricular septal defect (VSD) in the
middle third of the interventricular
septum (IVS) with diameters
-should determine
CK-MB and
myoglobin SLs and
myoglobin urinary
concentration
(because these
rhabdomyolysis
markers were not
determined until the
moment of this
consult by dr. Dragoi)
*
-should start ARS
P.O. 30+0+0 ml/day
(=30 ml/day ~ 2
ml/body_kg/day) from
the first week of
August 2019: the 30 ml
fraction should be
administered before
meals; after 1 month
of ARS P.O., the daily
dose may be increased
to 30+30+0 ml/day
(=30 ml/day ~ 4
ml/body_kg/day)
(parents didn’t apply
this increase until the
last week of January
2020) *
- should continue the
other combined DSs
(all started from April
2019) with the same
daily dosing as
previously applied:
Coenzyme Q10 (30 mg
/day), L-carnitine
(1g/day) & Vitamin D3
(1000IU/day) & plant-
extracts
hepatoprotective syrup
(5ml/day); *
- may discontinue the
calcium-magnesium
oral DS (initial dose:
3
Body mass (BM): ~12.5 kg (percentile
~10: under average, but normal BM)
Body exam: he can independently stand,
walk and run; slight loss of muscular
strength (predominantly in axial muscles)
with mild kyphosis and lumbar
hyperlordosis, slight pseudohypertrophy of
calf muscles (both with 19.5 cm in
circumference),
marked psychomotor agitation (walks and
runs with a slightly enlarged sustaining
base [with higher than normal distance
between his feet]), didn’t collaborate for
Gower’s sign; no installed urethral and anal
sphincter control (he doesn’t announce his
imminent micturitions nor defecations);
normal cranial nerves; tight phimosis (with
one smegma pearl)
Mental examination: Language skills:
language development delay (with
predominant expressive language delay: he
uses only aprox. 5 Romanian words
[“mather” {“mama”}, “father” {“tata”},
“water” {“apa”} etc] which he clearly and
correctly spells and uses them
spontaneously; he only uses two verbs
“give me” [distorted] and “bye”, both
correctly used; he doesn’t build simple
sentences, he doesn’t even associate two or
more words together); inconstant visual
contact with examiner and parents when he
is called by name;
he can accomplish simple instructions (to
stand on his potty or to take out his
pampers by himself alone; he brings and
offers various objects at request; he points
various objects with his index finger or
hand at request); Social skills: he doesn’t
get closer to smaller children but he
sometimes wants to socialize with children
older than his age; Play skills: he uses toys
in normal ways (he doesn’t prefer atypical
toys like bottles, nor laces/cords/strings,
leafs etc); he likes to play with ball; he
likes to sprinkle water and sand and he
generally likes a lot to play with water and
in the water;
History: the boy was born from mother’s
first gestation (as first and single child until
present), born from a high risk pregnancy
(because of his mother having unilateral
kidney stone disease [KSD] and
complicated with acute pyelonephritis and
secondary fever and severe kidney
colic/pain in the 6th month of gestation [and
received antibiotics and specific
medication for KSD in hospital]);
Gestational age at birth 33 weeks; Body
mass at birth: 2.15kg; Apgar score: 6 (1
minute)/6 (after 5 minutes) (he was born
with respiratory insufficiency with
3/3.6mm (and secondary left-to-right
cardiac shunt), without atrial septal
defect (ASD) (formen ovale
functionally closed), with normal
cardiac valves;
Heart ultrasound (3) (age: 2 years
& 7 months): normal
(spontaneously healed VSD);
Heart ultrasound (4) (age: 2 years
& 10 months): normal
(reconfirming the spontaneously
healed VSD);
Abdominal ultrasound (age: 2
years & 5 months): normal;
*
ANTERIOR LABS (2.07.2016 [day
1 after birth]; 4.07.2016 [day 3
after birth], 18.07.2016 [~ 3 weeks
after birth]):
Hgb: 12.8 g/dl (vs Hb=10.5g/dl in
the 1st day after birth and after
blood transfusion);
ASAT serum level (SL): 162 U/l
ALAT SL: 34 U/l (within normal
range [wnr]);
CK SL: 9949 U/l [2.07.2019] vs
2037 U/l [as repeated on 4.07.2019]
CRP SL: 0.118 mg/l
Total bilirubin: 4.36 mg/dl (~ 4
times higher than the superior
limit of the normal range [slnr]);
Direct bilirubin: 0.19mg/dl (wnr);
Important note: Despite his
increased RSMs (ASAT and CK),
this boy wasn’t recommended any
neurological consult, nor
determination of CK-MB SL until
January 2019 (when he was 2 years
and 5 months old).
*
ANTERIOR LABS (routine
screening from 22.01.2019
conducted by a dermatologist and
accomplished in private lab from
Slobozia, screening done because
of some allergic manifestations of
the boy):
ASAT SL: 970.9 U/l (>20* slnr);
ALAT SL: 844.5 U/l (>20*slnr);
*
ANTERIOR LABS (routine
hepatitis screening from 30.01.2019
conducted by an infectionist from
the “Victor Babes” Infectious
Diseases Hospital from Bucharest):
-negative hepatitis B&C serologies;
-negative Toxocara serology;
ASAT SL: 685 U/l (>15*slnr)
ALAT SL: 770 U/l (>15*slnr);
5ml/day, started from
April 2019)
*
-should start omega-3
fatty acids dietary
supplement with
185mg/day (and may
increase to 370mg/day
after one month);
*
-should start physical
therapy sessions
-should start home
physical therapy daily
sessions (30-45
minutes/session and
even 2 sessions/day
when starting ARS
P.O.) *
-should continue
periodic neurological
consults (at least two
consults per
calendaristic year)
*
- while under ARS
P.O., he should be
tested with North Star
Ambulatory
Assessment (NSAA)
and with the 6-minute
walk test (6MWT)
each 6 months;
*
-psychological
extensive consult, for
speech therapy and
behaviour therapy
*
-other specific
alergologic tests and
alergologic consult
*
- screening the
phenotype of the
mother with GGT, CK
and CK-MB SLs
4
secondary marked cyanosis and altered
general state,
also associated with cloudy amniotic fluid:
he needed oxygen therapy at birth), systolic
heart murmur (grade III-IV/VI); he was
also born with anemia (with hemoglobin
level Hb=10.5g/dl) and he needed blood
transfusion with two units of blood (after
which hemoglobin increased to Hb=12.8
g/dl); he was kept in the lying-in hospital
for about 3 weeks;
Other important information:
Vaccination status: vaccinated up-to-date
(two doses of MMR vaccine [one 1st dose
at 10 months of age and one 2nd dose at 12
months of age] because of the measles
epidemic context in Romania);
-blood group: AB Rh+
-development quotient (DQ)=62% from
the normal for age and sex (according to
the psychologist who evaluated the child at
“Victor Gomoiu” children hospital)
Previous treatment (until 31.07.2019)
(prescribed by his attending neurologist
from the last week of February 2019): L-
carnitine (1g/day) & Vitamin D3
(1000IU/day) & calcium-magnesium oral
supplement (5ml/day) & plant-extracts
hepatoprotective syrup (5ml/day) &
coenzyme Q10 (30mg/day)
*
GGT SL: 10 U/l (wnr)
CK SL: 27 713 U/l (>200*slnr)
LDH SL: 5 317 U/l (a non-specific
marker for tissular damage, including
rhabdomyolysis, especially
myocardium damage)
*
ANTERIOR LABS (routine DMD
screening from 27.02.2019
conducted by a neurologist from
the “Victor Gomoiu” pediatric
hospital, BEFORE starting any
therapy):
ASAT SL: 860 U/l (>20*slnr)
ALAT SL: 770 U/l (>15*slnr);
CK SL: 24 000 U/l (>200*slnr)
LDH SL: 3 026 U/l
*
ANTERIOR LABS (routine check
after the first ~ 3 months of
treatment with DSs for DMD
conducted by the same neurologist
from the “Victor Gomoiu”
pediatric hospital):
ASAT SL: 311 U/l (>7*slnr)
ALAT SL: 356 U/l (>8*slnr);
CK SL: 18 350 U/l (>200*slnr)
LDH SL: 2 670 U/l
5
Consult no. 2 by dr.
Dragoi (24.01.2020)
(short online consult
for minimal
anamnesis and labs
reading)
Age: 3 years & 3 months (birth
date: 2.07.2016)
*
Body mass (BM): ~13 kg
(percentile ~15: under average,
but normal BM)
Anamnesis:
-online consult after ~6 months
of combined therapy with: ARS
P.O. (30ml/ day = 2.3 ml/ kgb/
day; parents didn’t increase
the ARS dose to 60ml/day
after the 1st month of
treatment with ARS) & L-
carnitine (1g/day) & Vitamin
D3 (1000IU/day) & plant-
extracts hepatoprotective
syrup (5ml/day) & coenzyme
Q10 (30mg/day)
-has also started speech
therapy and behaviour therapy
from autumn 2019
ANTERIOR LABS
(21.08.2019) (after ~3
weeks of ARS P.O. 30
ml/day (~2.3
ml/body_kg/day):
ASAT SL: 303 U/l
ALAT SL: 175 U/l
CK SL: 21 000 U/l
LDH SL: 3 448 U/l
*
ANTERIOR LABS
(2.12.2019) (after ~4
months of ARS P.O. 30
ml/day (~2.3
ml/body_kg/day):
ASAT SL: 241.98 U/l
CK SL: 7 885.7 U/l
LDH SL: 1 318.65 U/l
-should determine CK-MB and
myoglobin SLs and the myoglobin
urinary concentration (because these
rhabdomyolysis markers were not
determined until the moment of this
consult by dr. Dragoi)
*
-should continue ARS P.O. and
increases its dose up to 45+15+0
ml/day (=60 ml/day ~ 4.6
ml/body_kg/day); the ARS dose may
optionally be increased to 60+30+0
ml/day after the one month with 60 ml
ARS/day *
- should also continue the other
combined DSs (all started from April
2019 and continued up to present)
with the same daily dosing as
previously applied: Coenzyme Q10 (30
mg /day), L-carnitine (1g/day) &
Vitamin D3 (1000IU/day) & plant-
extracts hepatoprotective syrup
(5ml/day); *
-should continue omega-3 fatty acids
dietary supplement with 185mg/day (and
increase to 370mg/day at any time);
*
-should continue physical therapy
sessions
-should continue home physical therapy
daily sessions (30-45 minutes/session
and even 2 sessions/day when starting
ARS P.O.) *
-should continue speech therapy and
behaviour therapy *
-should continue periodic neurological
consult (at least two consults per
calendaristic year) *
- while under ARS P.O., he should be
tested with North Star Ambulatory
Assessment (NSAA) and with the 6-
minute walk test (6MWT) each 6
months; *
-psychological extensive consult, for
speech therapy and behaviour therapy
6
(Table 2. The rhabdomyolysis markers (serum levels) of this 3rd case report on ARS effects in DMD (presented in
chronological order))
Table 2. The rhabdomyolysis markers (serum levels) of this 3rd case report on ARS effects
in DMD (presented in chronological order)
Index
of lab
set
Date/interval of the
lab set and aprox.
age (A) of the boy
Location of lab
ASAT
(U/l)
ALAT
(U/l)
CK
(U/l)
LDH
1
2-18.07.2016
A: 1-3 weeks
Slobozia (maternity)
162
34
9949 [2.07.2019]
2037 [4.07.2019]
-
2
22.01.2019
Slobozia (private lab)
970.9
844.5
3
30.01.2019
“Victor Babeș” National
Institute of Infectious
Diseases (Bucharest)
685
770
27 713
5 317
4
27.02.-05.03.2019
“Victor Gomoiu” Pediatric
Hospital (Bucharest)
860
770
24 000
3 026
5
22-27.05.2019
(after ~4 months of
L-carnitine &
coenzyme Q10&
Vitamin D3 &
calcium-magnesium
supplement &
hepatoprotective
syrup)
“Victor Gomoiu” Pediatric
Hospital (Bucharest)
311
356
18 350
2 670
6
21-27.08.2019
“Victor Gomoiu” Pediatric
Hospital (Bucharest)
303
175
21 000
3 448
7
2-5.12.2019
(after ~4 months of
ARS & L-carnitine
& coenzyme Q10&
Vitamin D3 &
hepatoprotective
syrup)
“Victor Gomoiu” Pediatric
Hospital (Bucharest)
241.98
7885.7
1318.65
(Image 1. The evolution of the rhabdomyolysis markers serum levels (RMSLs) of this 3rd case of DMD)
Rhabdomyolisis markers serum levels (RMSLs) evolution
0
20
40
60
80
100
120
140
160
180
02/07/2016
02/10/2016
02/01/2017
02/04/2017
02/07/2017
02/10/2017
02/01/2018
02/04/2018
02/07/2018
02/10/2018
02/01/2019
02/04/2019
02/07/2019
02/10/2019
Calendaristic date
RMSLs (expressed in multiples of the
superior value of the normal range)
AST
ALT
CK
LDH
7
***
Results and Interpretations
1. The treatment with ARS P.O. in the first ~4 months (from the
1st week of August 2019 until the 1st week of December 2019)
plus the anterior and concomitant treatment with other
combined DSs (from the last week of February 2019 until the
1st week of December 2019) was associated with:
a. * a spectacular ~5-fold total decrease of ALAT SL (from
844.5 U/l [on 22.01.2019] to 175 U/l [on 21.08.2019])
b. * a spectacular ~4-fold total decrease of ASAT SL (from
970.9 U/l [on 22.01.2019] to 241.98 U/l [on 2.12.2019])
(with normal GGT serum levels on 31.01.2019 [10 U/l]:
the only available determination until present)
c. * a spectacular ~3.5-fold total decrease of CK SL (from
27713 U/l [on 22.01.2019] to 7885.7 U/l [on 2.12.2019])
d. * a spectacular ~4-fold total decrease of LDH SL (a non-
specific marker for tissular damage, including
rhabdomyolysis, especially myocardium damage) (from
5317 U/l [on 22.01.2019] to 1318.65 U/l [on 21.08.2019])
e. (all * markings): under the reserve that CK-MB and
myoglobin (MG) serum levels were never determined for
this boy and never specifically requested by any doctor
except dr. Drăgoi;
f. These significant decreases of the (previously) listed
rhabdomyolysis markers may be explained by the fact that
ARS has strong global NRF2 activation effect (on all
types of muscles/myocytes) and a very strong NRF2
activation effect on the myocardium, where the
expression of NRF2 is larger than in skeletal muscles, an
additional indirect subtle potential “proof” that ARS acts
via NRF2 pathway). These results suggest that ARS may
have very potent muscular (including myocardial)
protective effects (the basis of which we propose the study
of ARS on large cohorts with acute or chronic cardiac
diseases), significantly limiting the muscular damage in
DMD patients, with the potential of even stronger effects
in (milder) BMD phenotypes: this comes in the “same
pack” with no liver toxicity, no adverse effect on growth
and development of the child and no other adverse effects
in other clinical spheres until the present. Additional note.
ARS (combined with other DSs) actually tends to
transform a severe DMD phenotype in a milder BMD
phenotype.
g. For extensive interpretations of ARS effects in all three
DMD cases (published by the author) see reference
[Error! Bookmark not defined.] (section ”Results and
Interpretations”).
h. The next labs scheduled for this child in spring 2020 were
postponed due to Covid-19 pandemics.
i. Because this DMD boy has no muscle biopsy until present
(thus has no molecular studies on his mutant dystrophin)
***
Discussions
1. For previous extensive discussions on ARS effects in all three
DMD cases treated with ARS as adjuvant (published by the
author) see reference [1] (section ”Discussion”).
2. The concomitant determination of myoglobin concentrations
in both serum and urine would have been very useful in
clearly differentiating between a lower loss of myoglobin
from muscles cells into blood VERSUS a higher rate of
myoglobin elimination in urine (which both may express by
lower serum levels of myoglobin): two (out of the three
families) didn’t had the financial resources to determine serum
myoglobin for their DMD boys and NONE of those three
distinct families had the financial resources to accomplish
both myoglobin tests concomitantly and that may be a
significant drawback in studying DMD cases treated with
ARS in Romania or other poor countries.
3. Pathophysiology [4]. The pathological mechanisms of DMD
are generally complex and dramatic: the main hallmark of
DMD is a very high oxidative stress (OS) level in DMD-
phenotype myocytes including cardiomyocytes (leading to
chronic muscle inflammation, repeated cycles of degeneration
and impaired muscle regeneration) [URL1, URL2, URL3,
URL4, URL5, URL5, URL6, URL7, URL8, URL9, URL10,
URL11, URL12, URL13, URL14, URL15, URL16]
a. OS is two sided: whereas excessive OS causes
intracellular molecular damage, maintenance of a
physiological level of oxidant challenge (mainly by
superoxide molecules generation), termed oxidative
eustress” (OES), is essential for governing life processes
through redox signaling. “Redox balance is maintained
by prevention, interception, and repair, and
concomitantly the regulatory potential of molecular
thiol-driven master switches such as NRF2/Keap1 or
NF-κB/IκB is used for system-wide OS response. Non-
radical species such as hydrogen peroxide (H2O2) or
singlet molecular oxygen, rather than free-radical
species, perform major second messenger functions.
Chemokine-controlled NADPH oxidases and
metabolically controlled mitochondrial sources of H2O2
as well as glutathione- and thioredoxin-related pathways,
with powerful enzymatic back-up systems, are
responsible for fine-tuning physiological redox
signaling. This makes for a rich research field spanning
from biochemistry and cell biology into nutritional
sciences, environmental medicine, and molecular
knowledge-based redox medicine. [URL1, URL2,
URL3].
b. ARS contains both superoxide and H2O2 species (in
small concentrations<1%) and not only hyper-activates
NRF2, but also "injects" cells with various free radical
8
species, thus keeping OES while preventing a possible
cytotoxic reductive stress (RS): that is what makes ARS
unique from all known natural/artificial antioxidants; in
contrast, common antioxidants may easily induce RS
when given/administered in excess or when too strongly
activating the NRF2 pathway [URL1, URL2, URL3,
URL4, URL5, URL6, URL7, URL8] (although there
may be cases in which a slight RS may prevent OS: see
URL). More specifically, even if ARS is a solution in
which there is a relatively good redox balance between
free oxidant species (FOS) and free reductive species
(FRS), ARS has an ~3-4 acid ph (as its superoxide and
other FOS slightly predominate over FRS). The direct
antioxidant effect of ARS is probably low, although
"injecting" ARS in a cell under oxidative stress actually
(and at least partially) restores the balance between FOS
and FRS in that cell. In the same time FOS from ARS
strongly (and very selectively) activates NRF2 and all
the endogenous antioxidant enzymatic systems
controlled by NRF2: apparently this may lead to RS, but
this probably does not happen in case of ARS just
because ARS ALSO injects cells with some additional
FOS (which probably remain partially non-neutralized
by endogenous antioxidant systems) and that is unique
among all direct antioxidants and among all known
NRF2 activators. In a cell under high OS, ARS strongly
lowers the global oxidative level/potential from/of that
cell (not mainly by direct mechanism, but mainly by
NRF2 activation and consequent endogenous antioxidant
enzymes genetic overexpression) and in the same time
"injects" additional FOS species in the cell, thus
preventing reductive stress. It is true that ARS also
"injects" FRS in that same cell, but those FRS are in
minority (when compared to FOS predominance in
ARS). Prudence is however advised so that ARS
should be administered in progressively higher doses
(correlated with the body mass of the patient) so that
to effectively treat OS without causing RS:
(explanation 1) RS may have also caused the slight re-
increase of ASAT, ALAT, CK and CK-MB (in the
lastly reported period of treatment) in the 1st
published case of an ARS-treated boy with DMD
[Error! Bookmark not defined.]; (explanation 2) another
possible explanation for this slight re-increase (of those
rhabdomyolysis markers) may be an autoimmune
response to a possible increase in the number of normal
dys revertant fibers (plausibly induced by ARS) to which
organisms with DMD phenotypes (DPs) haven’t
normally gained an immune tolerance because the low
levels of normal dys in these DPs (a phenomenon
already demonstrated after exon‐skipping therapy in a
mdx mouse model: see URL). Furthermore, there is a
very high variability between human individuals in their
cellular response to physical exercise (PE) (aka “redox
individuality”): because ARS grossly contains the same
redox molecules that are usually produced in cells by PE,
the response to ARS is also expected to be very variable
(concerning the possible induction of OS and/or RS) in
general, and even more variable in DMD cases in which
there is a very large spectrum of possible dys gene
mutations (affecting dys structure and functions in the
human cells). Given its uniqueness in possibly
preventing RS, ARS should replace common
antioxidants in all those past studies (which should be
redesigned by including ARS) in which those tested
antioxidants or NRF2 activators were demonstrated
to not help and even to induce RS.
c. The strong stimulation of lipid metabolism induced by
ARS through higher rate of tissular lipolysis [1,2] (with
significantly higher energy production produced by
partial switching from a glucidic to a lipidic metabolism)
may very plausible help the skeletal and cardiac muscles
to overcome the high oxidative stress (characteristic to
DMD muscles) and help those muscles to repair and/or
regenerate with significantly higher efficiency.
d. The spectrum of diseases (including genetic syndromes)
which have an important component of acute and/or
chronic OS is immense, that is why ARS has a
significant potential to help in all these diseases, and that
is why ARS deserves systematic extensive studies in
many diseases from this OS-centered spectrum of
diseases.
e. ARS is such a potent indirect antioxidant (via NRF2
pathway) that it can be also used as a research tool to
indicate/verify if any disease has a significant oxidative
stress component or not: for example, the significant
decrease of all rhabdomyolysis markers (when under
ARS P.O.) in these published cases of DMD clearly
indicates that DMD has an important oxidative stress
component. More specifically, ARS can be administered
in any clinical case even when no specific/exact
diagnostic is known: if there will be any clinical or
paraclinical amelioration in that clinical case with
unknown diagnosis, then OS is probably one important
link in the pathophysiology of that
unknown/undiagnosed disease.
4. Additional lab/imaging and other tools for studying DMD
cases treated with ARS in the future [4]. Impaired muscle
regeneration is a hallmark in DMD, that is why several indices
of regeneration (centronucleation, fibre size, embryonic
myosin, utrophin serum levels [URL]) can also be measured
in ARS-treated DMD/BMD cases.
a. LDH [URL2], which is expressed extensively in almost all
body tissues: it is released from the intracellular medium
during tissue damage, it is a marker of common injuries
9
and disease such as muscles damage (from DMD/BMD),
heart failure etc. [URL1a, URL1b, URL2, URL3, URL4,
URL5]
b. Diaphragm ultrasonography may also be used in the
future as a practical non-invasive assessment of the
diaphragm function in ARS-treated DMD cases [URL].
c. Various questionnaires and scores can be used to
quantify the quality of life in children and adults with
DMD [URL].
d. FORT [URL2] and FORD [URL2] tests may also be
used to periodically monitor the antioxidant properties in
any ARS-treated patient (not only in ARS-treated
DMD/BMD patients).
e. Hand-held myometry [URL1, URL2, URL3, URL4,
URL5]
f. 6 Minute Walk Test [URL2] (6MWT) [URL1, URL2a,
URL2b, URL3, URL4a, URL4b, URL5, URL6, URL7,
URL8, URL9, URL10, URL11] and its 2MWT variant
(URL1)
5. Additional diets and molecules which may have synergic
effects with ARS [4]. Possible synergic combinations
between ARS and other therapeutic molecules also deserve
extensive studies:
a. Various diet-charts for DMD patients [URL]
b. Specific physical therapies [URL]
c. creatine monohydrate (URL)
d. simvastatin (URL1, URL2)
e. N-acetylcysteine (NAC) (URL; ARS may even be
studied in combination with [or as a replaces of] NAC
in paracetamol/acetaminophen intoxication/poisoning,
because, similarly to NAC, ARS also increases the
concentration of glutathione in all cells, including
hepatocytes by activating glutathione synthase via
NRF2 pathway)
f. melatonin [URL]
g. Medical laser [URL]
h. SIRT1 activators [URL]
i. Protandim® (a NRF2 activating combination of herbal
dietary supplements) [URL]
j. various vitamins: vitamin C, vitamin E, vitamin D3,
vitamins from the B complex etc.
6. Other potential uses of ARS [4].
a. Given the spectrum of NRF2 cellular/tissular different
concentrations (kidney > muscles > lungs > heart > liver
> brain), ARS (as a very efficient NRF2 activator with
excellent bioavailability in all these listed vital organs)
has a significant therapeutic potential in renal, hepatic,
pulmonary, heart, liver and even brain infectious and/or
inflammatory and/or degenerative diseases (possibly also
including mental disorders like depression, anxiety etc).
Given that kidneys have the highest NRF2 tissular
concentration, ARS deserves a special focus in studying
the treatment with ARS PO in various
nephrologic/kidney disease like: various types of
(progressive) glomerulonephritis, nephrotic syndrome,
urinary tract infections (UTIs) (especially
pyelonephritis), chronic kidney disease (CKD) and even
hemolytic-uremic syndrome (HUS) and even Covid-19
(which, by triggering endothelial inflammation,
frequently has heart, renal and coagulation
complications, not only pulmonary complications) so
that to prevent renal scaring or other possible mild or
serious complications of these kidney diseases.
b. Given its “hybrid” antimicrobial and anti-inflammatory
effects (plus its demonstrated stability in nebulized
form), ARS deserves extensive studies on its possible
capacity to prevent airway tract infections similarly to
inhaled antibiotics in recent specific studies on DMD
patients with respiratory distress/insufficiency [URL] of
various infectious or non-infectious etiologies.
c. ARS may be tested as adjuvant in various doses (2-3-4-
5-..10 ml x 1-2-3/day) as adjuvant treatment with
possible good results on pulmonary/airways
inflammation (because of its anti-inflammatory
properties via NRF2 pathway) and viral/bacterial
infections (because of its direct bactericidal and virucidal
properties).
d. Given its corticoid-like anti-inflammatory effects, ARS
also deserves extensive studies (alone or in various
combinations with inhalatory, oral or parenteral
corticosteroids) in all diseases which usually respond to
corticoids, like pulmonary sarcoidosis, primary or
secondary pulmonary fibrosis, cystic fibrosis (because
of its hybrid anti-microbial and anti-inflammatory
mechanism), scleroderma with pulmonary determination
(because ARS significantly diminishes chronic
inflammation and thus may prevent fibrosis). The results
may be even better when ARS nebulizations are
associated with ARS consumption PO. Of course that
ARS may be first tested on various mouse models of
chronic pulmonary inflammation of various infectious,
autoimmune, genetic and non-genetic diseases.
e. ARS may also have some interesting effects on
extracellular matrix (EM) and interstitial (stromal) cells
(ICs), especially on telocytes, which are a novel defined
type of ICs (in the field of stem cells), with very long
(tens to hundreds of micrometres) and very thin
prolongations called telopodes: these telopodes present
an alternation of thin segments called podomeres (with
caliber mostly < 200 nm, below the resolving power of
light microscopy) and dilated segments calledpodoms,
which accommodate a relatively large number of
mitochondria (on which ARS was proven to have some
significant effects via NRF2 pathway but also via other
10
genetic pathways [see the 1st published case on ARS
effects in DMD]), (rough) endoplasmic reticulum and
caveolae - the so-called "Ca2+ uptake/release units".
***
Final conclusions [4]
1. ARS is plausibly the strongest (artificial) NRF2 selective
activator ever produced by humans in a lab: that is why ARS
may be regarded as a very important discovery in redox
medicine and human/animal medicine/biology in general.
2. ARS effects in DMD patients appear to be reproducible,
because the response to ARS is quite similar in all these three
published ARS-treated DMD cases: that makes ARS a very
promising new strategy to be further studied in DMD and
BMD treatment/management. Furthermore, we predict that
ARS effects in BMD patients (which have a less affected
phenotype) may be even more remarkable.
3. Obviously, further extensive studies are needed to better
understand the cellular effects of various ARS dosages and
ARS combinations with other (possibly synergistic)
therapeutic molecules/drugs (as previously detailed).
4. ARS therapy is significantly more expensive than oral
corticosteroids but ARS therapy has the advantage to have
zero toxicity (in principle) and to be significantly less
expensive than ataluren or exon skipping therapy for example.
***
Acknowledgments [4]
1. Funding: All the pediatric consults and all the dietary
supplements (including ARS) given/administered to this boy
were financially supported by his parents, because these
therapeutic substances are not supported by the Romanian
National Health Insurance System (RNHIS);
2. Author contributions: The conceptualization, data curation,
formal analysis, investigation, methodology, project
administration, software (used for keeping the evidence of all
patients, including this boy), supervision, validation,
visualization, writing (the original draft plus review & editing)
were all done by dr. Andrei-Lucian Drăgoi, the single author
of this article. Funding acquisition and resources were mainly
supported by the parents of this boy and secondarily supported
by RNHIS; we have also obtained the oral consent of the
mother to publish this medical case in both English and
Romanian, with the only condition to not mention the names
of the boy, parents or other relatives;
3. Competing interests: the author of this paper was invited a
couple of times to present ARS and his clinical experience
with ARS, but with no financial remuneration and no
competing interests.
***
References
(most of the references were already included as hyperlinks/URLs
in the text)
[
1
] Andrei-Lucian Drăgoi (July 2019). (ASEA in DMD - CJBRT article - 20.07.2019) The
Remarkable Effects of “ASEA redox Supplement” In A Child with Duchenne Muscular
Dystrophy A Case Report, Canadian Journal of Biomedical Research and Technology
(CJBRT) 2019; volume 1, issue 4:8. ISSN: 2582-3663. URLs: URL1a, URL1b, URL1c
(CJBRT original sources); URL2a (Research Gate source); URL2b & URL2c (Academia
sources); URL2d (Vixra source); URL3 (Research Gate preprint source). See also the newly
released related add-on paper (RG preprint) The 1st case report on the remarkable effects
of “ASEA Redox Supplement” (ARS) in a boy with Duchenne muscular dystrophy (DMD) –
periodic updates released after 20.07.2019 (the date of the official case publication in a peer-
reviewed journal) (DOI 10.13140/RG.2.2.23141.76002, URL to RG preprint).
[
2
] Andrei-Lucian Drăgoi (May 2018). (ASEA in DMD preprint version 1.1 1.08.2018
13 pages) The clinical and biological effects of ASEA ionized water /”redox supplement”
(co-administered with L-carnitine and omega-3 fatty acids plus multivitamins dietary
supplements) in a ~3-year-old boy with Duchenne muscular dystrophy (DMD) from
Romania a case report. Research Gate preprint. DOI: 10.13140/RG.2.2.21420.36486. URL
(Research Gate source). 2 Recommendations from: Syed Ismyl Mahmood Rizvi and P.F.
Zabrodskii. The article based on this preprint was published in July 20th, 2019 under the title
“The Remarkable Effects of “ASEA redox Supplement” In A Child with Duchenne Muscular
Dystrophy A Case Report” in the Canadian Journal of Biomedical Research and Technology
(CJBRT) 2019; volume 1, issue 4:8. URLs: URL1a, URL1b, URL1c (CJBRT original
sources); URL2 (Research Gate source)
[
3
] Andrei-Lucian Drăgoi (November 2nd, 2019). (Asea in DMD conferința Râmnicurat -
45 slides - 2.11.2019) Efectele remarcabile ale suplimentului redox "Asea"® în 2 cazuri
de distrofie musculară Duchenne la copil și potențialul terapeutic al Asea în bolile acute
și cronice cu o importantă componentă de stres oxidativ celular. Presentation and
conference paper also published on Research Gate with DOI (of RG presentation):
10.13140/RG.2.2.28023.78240 [URL2]. URL1a (Research Gate main source; see also
URL1aa), URL1b (Academia secondary source). URL1c (Vixra secondary source), URL1d
(GSJ secondary source), URL1e (dragoii.com latest variant source).
[
4
] Andrei-Lucian Drăgoi (August 30th, 2019). (ASEA in DMD 2nd case preprint - v.1.0 -
30.08.2019 - 10 pages) A Second Case Report Regarding the Effects of "ASEA redox
Supplement" in a ~5-year old boy with Duchenne Muscular Dystrophy from Bucharest,
Romania (preprint). Research Gate preprint with DOI: 10.13140/RG.2.2.18399.41128.
URL1a (Research Gate main source), URL1b (Academia secondary source), URL1c (Vixra
secondary source), URL1d (dragoii.com latest variant source), URL1e (GSJ secondary
source).
[
5
] Andrei-Lucian Drăgoi (November 23rd, 2019). (Ataluren in DMD - version 1.0 -
23.11.2019 - 5 A4 pages) A proposed extension of Ataluren indications (with future
deserved studies) in patients with Duchenne muscular dystrophy (DMD) caused by
frameshift mutations of dystrophin gene associated with abnormal premature
termination codons (PTCs) at distance from the site of that given frameshift mutation.
Research Gate preprint with DOI: 10.13140/RG.2.2.21648.76804. URL1a (Research Gate
main source), URL1b (Academia secondary source). URL1c (Vixra secondary source),
URL1d (GSJ secondary source), URL1e (dragoii.com latest variant source).
[
6
] Andrei-Lucian Drăgoi (February 29th, 2020). (NADS in COVID-19 - short communication
- version 1.0 - 1.5 A4 pages when excluding references - 29.02.2020) Potent NRF2-
activating dietary supplements (like resveratrol, curcumin, sulforaphane, “Asea redox
supplement” [ARS]) should be clinically tested as adjuvants in all types of medium and
severe cases of aggressive respiratory viral infections (including Influenza A/B/C, SARS,
MERS, COVID-19) based on their extrapolated cytoprotective antioxidant effects.
Research Gate preprint with DOI: 10.13140/RG.2.2.33764.12163. URL1a (Research Gate
main source), URL1b (Academia secondary source). URL1c (Vixra secondary source).
URL1e (dragoii.com latest variant source).
ResearchGate has not been able to resolve any citations for this publication.
Presentation
Full-text available
TITLE IN ENGLISH: The remarkable effects of " >® redox supplement" (ARS) in 2 cases of Duchenne muscular dystrophy in children and the therapeutic potential of Asea / ARS in acute and chronic diseases with a significant component of cellular oxidative stress) ABSTRACT IN ENGLISH: This research aims at discovering dietary supplements which may show comparable or even stronger beneficial effects (with less or none adverse effects) than corticosteroids in children with Duchenne Muscular Dystrophy (DMD). This paper presents a case report on the effects of an ionized “saline water” called “ASEA redox Supplement®” (ARS) oral solution in a ~2-year-old boy with DMD from Bucharest, Romania. In vitro studies showed that ARS is a very potent selective NRF2 activator, thus a very potent (indirect) antioxidant: the studies conducted in vivo also support this main pharmacological mechanism of ARS, with no toxicity up to high doses, in contrast with the much more toxic corticosteroids. From the first months of ARS treatment all the rhabdomyolysis markers (with very high initial serum levels) dropped significantly, with no found toxicity. The main conclusions of this paper are: (1) ARS has remarkable antioxidant and immunomodulatory effects and should be studied on larger groups of children with DMD under the age of 4 years old (but also on other age groups of children and even young adults), as an alternative to early corticosteroids; (2) Given its immunomodulatory effect (NRF2 selective activation and NF-kB inhibition), ARS deserves future cohort studies on its potential to replace corticosteroids and other non-steroidal immunosuppressants (at least partially) in many types of pulmonary/renal/hepatic/ articular/skin autoimmune and even malignant diseases of both children and adults; (3) Given its very strong antioxidant effects (by highly selective NRF2 potent activation), ARS deserves future cohort studies on acute/chronic diseases that imply high levels of tissular oxidative stress, especially some acute/chronic cardiovascular and respiratory diseases like acute myocardial infarction with acute/chronic heart failure, stroke, Chronic Obstructive Pulmonary Disease (COPD), asthma etc. of both children and adults (so that ARS may help millions and even billions worldwide). Keywords: ASEA redox supplement (ARS) oral solution, 3-year-old boy, Duchenne muscular dystrophy (DMD), NRF2 selective activation, corticosteroids --------------------------------- REZUMATUL LUCRARII/PREZENTARII (Rezumatul lucrării/prezentării) Această cercetare își propune să descopere suplimente alimentare care pot demonstra efecte benefice comparabile sau chiar mai puternice (cu efecte adverse mai mici sau deloc) decât corticosteroizii la copiii cu distrofie musculară Duchenne (DMD). Această prezentare conține 2 raporturi de caz (în premieră mondială) asupra efectelor unei soluții saline ionizate (de uz intern oral) numite "supliment redox < >”® (SRA) la doi băieței cu DMD de 4 respectiv 5 ani, ambii din București. Studiile in vitro au arătat că Asea este un foarte potent activator selectiv al factorului de transcripție nucleară NRF2 (ce guvernează răspunsul anti-stress celular de fază B), deci un antioxidant foarte puternic (indirect): studiile efectuate in vivo până în prezent susțin și ele acest principal mecanism farmacologic de acțiune al Asea, fără toxicitate demonstrată in vivo chiar până la doze relativ mari, în contrast cu toate tipurile de corticosteroizi, care au toxicitate demonstrată pe multe aparate și sisteme. Încă din primele luni de tratament cu Asea, toți markerii de rabdomioliză (cu niveluri serice inițiale foarte mari, tipice pentru DMD) au scăzut semnificativ, fără nici un semn clinic și/sau paraclinic de toxicitate. PRINCIPALELE CONCLUZII ALE ACESTUI ARTICOL (Principalele concluzii ale acestei lucrări) sunt: (1) Asea are efecte antioxidante și imunomodulatoare remarcabile și merită studiată pe grupuri mai mari de copii cu DMD cu vârsta sub 4 ani (dar și pe alte grupe de vârstă de copii și chiar adulți tineri), ca alternativă la corticosteroizii administrați precoce încă de la vârsta de 2-3 ani (cu cel puțin 1 an înainte de vârsta standard de 4 ani actualmente unanim acceptată ca moment de inițiere corticoizi în DMD); (2) Având în vedere efectul său imunomodulator (activarea selectivă a NRF2 și inhibarea factorului de transcripție NF-kB, ce guvernează răspunsul anti-stress celular de fază A), Asea merită studii viitoare de cohortă asupra potențialului său de a înlocui (cel puțin parțial!) corticosteroizii și alte imunosupresoare nesteroidiene în multe tipuri de boli pulmonare / renale / hepatice / boli autoimune articulare / cutanate și chiar maligne ale copiilor și adulților; (3) Având în vedere efectele antioxidante foarte puternice (prin hiper-activare înalt selectivă a NRF2), Asea merită studii viitoare de cohortă în bolile acute / cronice care implică niveluri ridicate de stres oxidativ tisular/celular, în special unele boli cardiovasculare și respiratorii acute / cronice precum infarctul miocardic acut cu insuficiență cardiacă acută / cronică, accident vascular cerebral, boală pulmonară obstructivă cronică (BPOC), astm bronșic etc. atât la copii cât și la adulți (astfel încât Asea poate ajuta milioane și chiar miliarde de bolnavi la nivel mondial). Cuvinte-cheie: supliment redox Asea (SRA) soluție orală, distrofie musculară Duchenne (DMD), factorii de transcripție nucleară NRF2 și NF-kB, activare selectivă de NRF2, corticosteroizi This paper belongs to a series of three cases on Asea effects in DMD children-patients: https://www.researchgate.net/publication/325371161 (1st case - preprint), https://www.researchgate.net/publication/334596031 (1st case - CJBRT article), https://www.researchgate.net/publication/334773748 (1st case - periodic updates), https://www.researchgate.net/publication/335502350 (2nd case - preprint), https://www.researchgate.net/publication/340902127 (3rd case - preprint); See also: https://www.researchgate.net/publication/336990483 and https://www.researchgate.net/publication/337026408 (ppt on Asea), https://www.researchgate.net/publication/339592997 (on possible testing of NRF2 activators in COVID-19)
ASEA redox Supplement" In A Child with Duchenne Muscular Dystrophy -A Case Report
  • Andrei-Lucian Drăgoi
Andrei-Lucian Drăgoi (July 2019). (ASEA in DMD -CJBRT article -20.07.2019) The Remarkable Effects of "ASEA redox Supplement" In A Child with Duchenne Muscular Dystrophy -A Case Report, Canadian Journal of Biomedical Research and Technology (CJBRT) 2019; volume 1, issue 4:8. ISSN: 2582-3663. URLs: URL1a, URL1b, URL1c (CJBRT original sources);
ASEA Redox Supplement" (ARS) in a boy with Duchenne muscular dystrophy (DMD) -periodic updates released after 20.07.2019 (the date of the official case publication in a peerreviewed journal
URL3 (Research Gate preprint source). See also the newly released related add-on paper (RG preprint) The 1st case report on the remarkable effects of "ASEA Redox Supplement" (ARS) in a boy with Duchenne muscular dystrophy (DMD) -periodic updates released after 20.07.2019 (the date of the official case publication in a peerreviewed journal) (DOI 10.13140/RG.2.2.23141.76002, URL to RG preprint).
ASEA in DMD preprint -version 1.1 -1.08.2018 -13 pages) The clinical and biological effects of ASEA ionized water /"redox supplement" (co-administered with L-carnitine and omega-3 fatty acids plus multivitamins dietary supplements) in a ~3-year-old boy
  • Andrei-Lucian Drăgoi
Andrei-Lucian Drăgoi (May 2018). (ASEA in DMD preprint -version 1.1 -1.08.2018 -13 pages) The clinical and biological effects of ASEA ionized water /"redox supplement" (co-administered with L-carnitine and omega-3 fatty acids plus multivitamins dietary supplements) in a ~3-year-old boy with Duchenne muscular dystrophy (DMD) from
ASEA in DMD 2nd case preprint -v.1.0 -30.08.2019 -10 pages) A Second Case Report Regarding the Effects of
  • Andrei-Lucian Drăgoi
Andrei-Lucian Drăgoi (August 30 th, 2019). (ASEA in DMD 2nd case preprint -v.1.0 -30.08.2019 -10 pages) A Second Case Report Regarding the Effects of "ASEA redox Supplement" in a ~5-year old boy with Duchenne Muscular Dystrophy from Bucharest, Romania (preprint). Research Gate preprint with DOI: 10.13140/RG.2.2.18399.41128. URL1a (Research Gate main source), URL1b (Academia secondary source), URL1c (Vixra secondary source), URL1d (dragoii.com latest variant source), URL1e (GSJ secondary source).
Asea redox supplement" [ARS]) should be clinically tested as adjuvants in all types of medium and severe cases of aggressive respiratory viral infections (including Influenza A/B/C, SARS, MERS, COVID-19) based on their extrapolated cytoprotective antioxidant effects
  • Andrei-Lucian Drăgoi
Andrei-Lucian Drăgoi (February 29 th, 2020). (NADS in COVID-19 -short communication -version 1.0 -1.5 A4 pages when excluding references -29.02.2020) Potent NRF2-activating dietary supplements (like resveratrol, curcumin, sulforaphane, "Asea redox supplement" [ARS]) should be clinically tested as adjuvants in all types of medium and severe cases of aggressive respiratory viral infections (including Influenza A/B/C, SARS, MERS, COVID-19) based on their extrapolated cytoprotective antioxidant effects. Research Gate preprint with DOI: 10.13140/RG.2.2.33764.12163. URL1a (Research Gate main source), URL1b (Academia secondary source). URL1c (Vixra secondary source).